HQY SEC Form 4 filings

Healthequity, Inc. Latest Insider Trading Activity

Our insider trading activity tracker for Healthequity, Inc. shows 12 total open-market insider transactions for HQY over the past 364 days. The latest displayed record by transaction date reports 2 purchases by Rajasekar Sunil (Healthequity, Inc. EVP Chief Prod & Strat Officer) totaling 131 shares at a weighted-average price of $91.16 per share, with the latest transaction dated October 15, 2026. This page shows up to the 10 most recent SEC Form 4 filing records on a 6-hour delay. Sign up for real-time updates and access to 20 years of historic insider trading data.

Insider Trading For HQY Charted on Daily Candles. Scroll left or zoom out to load earlier candles (up to 2 years).

▲ Insider buy ▼ Insider sale
Loading daily price history…
Charting by TradingView Lightweight Charts
Ticker Filing Date Transaction Date Company Insider Title Transaction Trade Count Shares Avg. Price Total Value Position Size Change SEC Filing
Unexplained: transactions without an ESPP, DRIP, 10b5-1, tax liability, or Explained M/S tag. HQY 2026-10-19 2026-10-15 Healthequity, Inc. Rajasekar Sunil EVP Chief Prod & Strat Officer Buy 2 131 $91.16 $11,942.02 0.25% View Filing
Unexplained: transactions without an ESPP, DRIP, 10b5-1, tax liability, or Explained M/S tag. HQY 2026-10-19 2026-08-24 Healthequity, Inc. Rajasekar Sunil EVP Chief Prod & Strat Officer Sell 2 131 $101.60 $13,309.43 0.25% View Filing
10b5-1: Scheduled Form 4 Transaction HQY 2026-06-02 2026-05-29 Healthequity, Inc. Fiore Michael Henry EVP, CHIEF COMMERCIAL OFFICER Sell 1 3,142 $95.00 $298,490.00 5.05% View Filing
10b5-1: Scheduled Form 4 Transaction HQY 2026-06-01 2026-05-28 Healthequity, Inc. Wellborn Gayle Furgurson Director Sell 1 2,439 $90.00 $219,510.00 11.00% View Filing
10b5-1: Scheduled Form 4 Transaction HQY 2026-06-01 2026-05-28 Healthequity, Inc. Ladd Delano EVP, General Counsel Sell 1 7,500 $90.00 $675,000.00 7.60% View Filing
10b5-1: Scheduled Form 4 Transaction HQY 2025-12-23 2025-12-19 Healthequity, Inc. Ladd Delano EVP, General Counsel Sell 1 1,500 $94.72 $142,080.00 1.99% View Filing
Unexplained: transactions without an ESPP, DRIP, 10b5-1, tax liability, or Explained M/S tag. HQY 2025-12-19 2025-12-18 Healthequity, Inc. Rosner Elimelech EVP, CHIEF TECHNOLOGY OFFICER Sell 1 10,959 $95.45 $1,046,036.55 19.33% View Filing
Explained M/S: sale activity tied to share conversions or derivative-related share movements. HQY 2025-12-16 2025-12-12 Healthequity, Inc. Wellborn Gayle Furgurson Director Sell 1 4,339 $98.03 $425,352.17 18.03% View Filing
10b5-1: Scheduled Form 4 Transaction HQY 2025-11-24 2025-11-20 Healthequity, Inc. Ladd Delano EVP, General Counsel Sell 1 1,500 $104.56 $156,840.00 1.95% View Filing
10b5-1: Scheduled Form 4 Transaction HQY 2025-10-22 2025-10-20 Healthequity, Inc. Ladd Delano EVP, General Counsel Sell 1 1,500 $92.07 $138,105.00 1.91% View Filing

Pricing

Free Trial

10 trading days
$0

Explore every Premium feature before you pay.

  • Full platform access
  • 10 trading days
  • No credit card required
  • 20 years of alert history
  • Live alert directory updates
Start your free trial

Standard Monthly

Scheduled
$19.99 / month

Scheduled alerts with complete trade context.

  • Email and Telegram delivery
  • Alert intervals from every sixty minutes to once daily
  • Filter by insider title, buy/sell, transaction value, DRIP, ESPP, 10b5-1, and tax liability coverage transfers
  • Highlighted cluster transactions and SEC filing links
  • Access to the alert directory hourly refreshes
Choose Standard Monthly

Premium Monthly

Recommended
$29.99 / month

Fastest alerts with ticker-level control.

  • Everything in Standard
  • Instant delivery detection-to-outbound time averages 0.89 seconds
  • Alert intervals starting from one minute
  • Real time alert directory updates
Choose Premium Monthly
Student discount: Customers who sign up with a verified .edu email address receive 50% off for the first four years. On monthly plans, the first month is the full 75% off.
Alerts are based on public SEC filings and are provided for informational purposes only; they do not constitute financial advice.